ReBlood Actively Expands into Southeast Asian Markets, Deepening International Cooperation to Support Listing on U.S. Capital Markets
Summary
New York, NY, December 01, 2024 --( PR.com )-- ReBlood, a leading company in the global health technology and regenerative medicine sector, recently sent its senior team to Indonesia and Thailand to engage in in-depth discussions with local medical schools, hospitals, and several entrepreneurs about potential cooperation. Key discussion points included clinical application research of cell regeneration technology, local promotion of health management services, and market cooperation opportunities in regenerative medicine. Additionally, both parties preliminarily discussed the possibility of establishing a regenerative medicine center to provide more comprehensive cell technology and clinical services.In Indonesia, ReBlood explored the application scenarios of cell storage and regeneration technology in research and clinical settings with local well-known medical schools and hospitals. At the same time, through discussions with influential local entrepreneurs, a preliminary cooperation foundation for promoting health products and services was established.In Thailand, ReBlood is committed to integrating local high-end medical resources to explore pathways for popularizing regenerative medicine technology and strengthening the localization of health management services.Focusing on High-End Markets and Expanding ASEAN PotentialReBlood targets potential high-end customers in the Thai and Indonesian markets, which together have a total population of about 350 million, with an estimated 5% being potential customers, amounting to 17.5 million people. In the future, the company plans to use this as a starting point to gradually expand into other ASEAN markets such as Malaysia, Singapore, and the Philippines.